Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SUSTAIRE vs NASALIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
SUSTAIRE (budesonide/formoterol) is a fixed-dose combination of an inhaled corticosteroid (budesonide) and a long-acting beta2-adrenergic agonist (formoterol). Budesonide exerts anti-inflammatory effects by binding to glucocorticoid receptors, inhibiting inflammatory mediator release, and reducing airway hyperresponsiveness. Formoterol selectively activates beta2-adrenergic receptors in bronchial smooth muscle, causing bronchodilation via increased c AMP production.
Corticosteroid that reduces inflammation by inhibiting phospholipase A2, decreasing arachidonic acid release, and suppressing prostaglandin and leukotriene synthesis.
FDA-approved for maintenance treatment of asthma in patients aged 6 years and older,FDA-approved for maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults,Off-label: acute asthma exacerbations (as part of SMART therapy)
FDA: Management of seasonal or perennial allergic rhinitis symptoms,Off-label: Nonallergic rhinitis, nasal polyps
50 mg orally twice daily
2 sprays (100 mcg total) per nostril twice daily; maximum 8 sprays (400 mcg) per day in each nostril.
Terminal elimination half-life of 8-12 hours in healthy adults; prolonged in renal impairment.
Terminal elimination half-life: 1-2 hours; clinically, intranasal dosing achieves prolonged local effects with minimal systemic accumulation.
Budesonide: extensively metabolized in the liver via CYP3A4 to inactive metabolites; formoterol: partially metabolized via glucuronidation and O-demethylation, with minor CYP involvement.
Primarily hepatic via CYP3A4; undergoes extensive first-pass metabolism.
Primarily renal excretion (80-90% unchanged); minor biliary/fecal elimination (10-20%).
Primarily hepatic metabolism via CYP3A4; metabolites and unchanged drug excreted in feces (approximately 60%) and urine (approximately 40%, with <1% unchanged).
Approximately 95% bound to albumin.
High (approximately 80%), primarily bound to albumin.
0.2-0.3 L/kg; indicates limited extravascular distribution primarily in plasma and interstitial fluid.
Approximately 2.8 L/kg; indicates extensive tissue distribution.
Oral: 70-80% due to first-pass metabolism; intravenous: 100%.
Intranasal: Approximately 49% systemic absorption relative to intravenous administration; oral bioavailability <1% due to extensive first-pass metabolism.
GFR 30-59 m L/min: 50 mg once daily; GFR 15-29 m L/min: 25 mg once daily; GFR <15 m L/min: not recommended
No dosage adjustment required for renal impairment.
Child-Pugh A: 50 mg twice daily; Child-Pugh B: 25 mg twice daily; Child-Pugh C: 12.5 mg once daily
No specific guidelines; use with caution in severe hepatic impairment due to potential corticosteroid effects.
Weight-based: 0.5 mg/kg orally twice daily, max 25 mg per dose
Children 6-14 years: 1 spray (50 mcg) per nostril twice daily; maximum 4 sprays (200 mcg) per day in each nostril. Children ≥14 years: same as adult.
Age >65 years: initiate at 25 mg twice daily; monitor renal function
No specific adjustment; use lowest effective dose due to potential increased osteoporosis risk.
Long-acting beta2-adrenergic agonists (LABAs) increase the risk of asthma-related death. SUSTAIRE is contraindicated for use as primary therapy for acute asthma exacerbations. For asthma, use only as add-on therapy for patients not adequately controlled on low-to-medium dose inhaled corticosteroids (ICS) or whose disease severity warrants initiation of ICS and LABA.
None.
LABA-associated asthma-related death; cardiovascular effects (tachycardia, hypertension); paradoxical bronchospasm; hypokalemia; hyperglycemia; increased susceptibility to infections; adrenal insufficiency with systemic steroid withdrawal; acute asthma exacerbation management.
May cause growth suppression in children with prolonged use,Potential for adrenal insufficiency with systemic absorption,Nasal septum perforation and local irritation reported,Monitor for immunosuppression or infections (e.g., Candida)
Primary treatment of status asthmaticus or acute asthma exacerbations; severe hypersensitivity to any ingredient.
Hypersensitivity to flunisolide or any component,Untreated localized nasal mucosal infections (e.g., herpes simplex)
No significant food interactions. Grapefruit or grapefruit juice may increase systemic exposure; avoid excessive consumption. No specific dietary restrictions required.
No specific food interactions reported. However, avoid grapefruit and grapefruit juice as they may increase systemic absorption via CYP3A4 inhibition, though topical corticosteroids have minimal systemic bioavailability.
Pregnancy Category C. First trimester: risk of major malformations unknown, but animal studies show fetal harm. Second/third trimester: potential for fetal respiratory depression, hypotonia, and withdrawal syndrome with chronic use. Avoid use unless benefit outweighs risk.
FDA Pregnancy Category C. In animal studies, corticosteroids have been shown to be teratogenic at high systemic doses. However, intranasal flunisolide has minimal systemic absorption; therefore, fetal exposure is low. There are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if potential benefit justifies potential risk to the fetus. First trimester: insufficient data; avoid unless necessary. Second and third trimesters: no specific risks identified; limited data suggest safety.
Excreted in breast milk; M/P ratio approximately 0.24. Limited data suggests low infant dose (0.5-1% maternal weight-adjusted dose). Monitor infant for drowsiness and feeding difficulties. Consider risk-benefit.
It is not known whether flunisolide is excreted in human breast milk. Because many corticosteroids are excreted in human milk, caution should be exercised when intranasal flunisolide is administered to a nursing woman. M/P ratio: not available.
No standard dose adjustment recommended. Increased plasma volume may reduce drug levels; monitor clinical response. Avoid near term due to risk of neonatal depression. Use lowest effective dose for shortest duration.
No dose adjustment required. Pharmacokinetic changes during pregnancy (increased volume of distribution and clearance) may affect systemic corticosteroids but intranasal flunisolide undergoes minimal systemic absorption; clinical pharmacokinetic data during pregnancy are lacking. Use the lowest effective dose for the shortest duration.
SUSTAIRE is an inhaled corticosteroid (ICS) used for maintenance treatment of asthma. It is not indicated for acute bronchospasm. Rinse mouth with water after each use to prevent oral candidiasis. Titrate to lowest effective dose to minimize systemic effects. Monitor for growth suppression in children and adrenal insufficiency during stress or prolonged use.
NASALIDE (flunisolide) is a corticosteroid nasal spray for allergic rhinitis. Titrate to lowest effective dose to minimize systemic absorption. Advise patients to clear nasal passages before use. Monitor for nasal irritation, epistaxis, or rarely, septal perforation. Not for acute symptom relief; onset of action may take several days.
Use SUSTAIRE regularly as prescribed, not for sudden breathing problems.,Rinse your mouth with water after each use to prevent thrush.,Do not stop taking SUSTAIRE without consulting your doctor, even if you feel better.,Keep track of your symptoms and peak flow if advised.,Seek medical help if your rescue inhaler is not working or you need more puffs than usual.
Use regularly for best results; do not expect immediate relief.,Shake bottle gently before each use.,Prime the pump by spraying into the air 5-6 times before first use or if not used for 2 weeks.,Blow nose gently before spraying to clear nasal passages.,Insert nozzle into nostril, aim away from the septum, and spray while breathing in.,Avoid spraying into eyes; if contact occurs, rinse with water.,Rinse nozzle with warm water after each use to prevent clogging.,Do not exceed recommended dosage; overuse can lead to systemic side effects.,Contact doctor if symptoms worsen or persist after 3 weeks.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SUSTAIRE vs NASALIDE, answered by our medical review team.
SUSTAIRE is a Methylxanthine Bronchodilator that works by SUSTAIRE (budesonide/formoterol) is a fixed-dose combination of an inhaled corticosteroid (budesonide) and a long-acting beta2-adrenergic agonist (formoterol). Budesonide exerts anti-inflammatory effects by binding to glucocorticoid receptors, inhibiting inflammatory mediator release, and reducing airway hyperresponsiveness. Formoterol selectively activates beta2-adrenergic receptors in bronchial smooth muscle, causing bronchodilation via increased c AMP production.. NASALIDE is a Intranasal Corticosteroid that works by Corticosteroid that reduces inflammation by inhibiting phospholipase A2, decreasing arachidonic acid release, and suppressing prostaglandin and leukotriene synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SUSTAIRE and NASALIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SUSTAIRE is: 50 mg orally twice daily. The standard adult dose of NASALIDE is: 2 sprays (100 mcg total) per nostril twice daily; maximum 8 sprays (400 mcg) per day in each nostril.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SUSTAIRE and NASALIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SUSTAIRE is classified as Category C. Pregnancy Category C. First trimester: risk of major malformations unknown, but animal studies show fetal harm. Second/third trimester: potential for fetal respiratory depression, . NASALIDE is classified as Category C. FDA Pregnancy Category C. In animal studies, corticosteroids have been shown to be teratogenic at high systemic doses. However, intranasal flunisolide has minimal systemic absorpti. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.